Intravenous Abdominal infections, Bone and joint infections, Gynaecological infections, Respiratory tract infections, Skin and skin structure infections, Urinary tract infections
Adult: 1-2 g 6-8 hrly, up to 12 g daily given in 4-6 divided doses in severe infections. Doses are given by slow inj over 3-5 min or, by intermittent or continuous infusion. Child: ≥3 mth 80-160 mg/kg daily in 4-6 equally divided doses. Max: 12 g daily.
Intravenous Prophylaxis of surgical infections
Adult: 2 g 30-60 min prior to surgery, then 6 hrly for not more than 24 hr. For caesarean section: 2 g as a single dose as soon as the umbilical cord is clamped; a further 2 g dose 4 hr and 8 hr after the initial dose may be given if necessary. Child: ≥3 mth 30-40 mg/kg 30-60 min prior to surgery, then 6 hrly for not more than 24 hr.
Loading dose: 1-2 g. Maintenance dose: According to CrCl. Haemodialysis patient: Repeat loading dose after each dialysis session.
0.5-1 g 24-48 hrly.
0.5-1 g 12-24 hrly.
1-2 g 12-24 hrly.
1-2 g 8-12 hrly.
As intermittent inj: Dissolve cefoxitin 1 g in 10 mL and 2 g in 10 mL or 20 mL of sterile water for inj. As intermittent or continuous infusion: Add 50 mL or 100 mL of dextrose 5% or 10% inj, NaCl 0.9% inj, or other compatible IV soln to cefoxitin 1 g or 2 g.
Y-site: Anakinra, fenoldopam, filgrastim, hetastarch in normal saline, pantoprazole, pemetrexed, pentamidine.
Hypersensitivity to cefoxitin and other cephalosporins.
Patient w/ history of penicillin allergy, GI disease (particularly colitis) and seizure disorder. Renal impairment. Pregnancy and lactation.
Hypersensitivity reactions (e.g. maculopapular or erythematous rash, exfoliative dermatitis, pruritus, urticaria, eosinophilia, fever, angioedema); elevated serum creatinine and/or BUN concentrations, anaemia; transient increase in serum AST (SGOT), ALT (SGPT), LDH and alkaline phosphatase levels; jaundice; thrombophlebitis. Rarely, oliguria, renal toxicity, neutropenia, transient leucopenia, granulocytopenia, thrombocytopenia, bone marrow depression; GI effects (e.g. nausea, vomiting, diarrhoea). Potentially Fatal: Anaphylaxis, pseudomembranous colitis.
Monitor renal function periodically when used in combination w/ other nephrotoxic drugs; prothrombin time. Observe for signs and symptoms of anaphylaxis during 1st dose.
Reduces renal clearance w/ probenecid. Concurrent use of nephrotoxic agents (e.g. aminoglycosides, colistin, polymyxin B, vancomycin) may increase the risk of nephrotoxicity.
Positive direct antiglobulin (Coombs') test results. False-positive results in urine glucose determinations using cupric sulfate soln (Benedict's reagent, Clinitest®). Falsely elevated serum or urine creatinine values w/ Jaffe method.
Description: Cefoxitin inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Pharmacokinetics: Absorption: Not absorbed from the GI tract. Distribution: Widely distributed into body tissues and fluids (including bile, synovial and pleural); poorly penetrates CSF even w/ inflamed meninges. It crosses the placenta and enters breast milk. Plasma protein binding: Approx 70%. Metabolism: Converted to descarbamylcefoxitin (approx 2%; inactive). Excretion: Via urine (85% as unchanged drug). Plasma half-life: 45-60 min.
J01DC01 - cefoxitin ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Anon. Cefoxitin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/11/2014.Buckingham R (ed). Cefoxitin Sodium . Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/11/2014.Cefoxitin Sodium Injection, Powder, for Solution (Apotex Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/11/2014.McEvoy GK, Snow EK, Miller J et al (eds). Cefoxitin Sodium. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/11/2014.